Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Rheumatol Int ; 41(9): 1625-1631, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34173843

ABSTRACT

Before the initiation of biotherapy in the treatment of rheumatic diseases, it is highly recommended for the patients to be screened for latent tuberculosis infection (LTBI). The objective of this study is to identify the prevalence of LTBI among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) before the initiation of biologic therapy in the Moroccan biotherapy registry (RBSMR). A cross sectional study was conducted using the baseline data of the Moroccan biotherapy registry. Tuberculin skin test or IGRA test or both tests were done before starting anti-TNF treatment for screening LTBI. The comparisons between positive and negative LTBI patients according to rheumatic disease were examined using categorical comparisons. 259 patients were included in this study.94 patients had RA and 165 had SpA. The mean age of the RA patients was 50.49 ± 11.82 years with a majority of females (84%). The mean age for the SpA patients was 36 ± 13.7 years with a majority of males (67.3%). The prevalence of LTBI in the RBSMR was 21.6%. This prevalence was at 24.8% in SpA patients, while it was at 15.9% for RA patients. After the comparison between positive and negative LTBI patients according to rheumatic disease, no demographic, clinical, or therapeutic characteristics were statistically associated with LTBI. This study found that in an endemic TB country like Morocco, a high prevalence of patients with SpA and RA had LTBI, and that RA patients had a lower prevalence than SpA patients.


Subject(s)
Arthritis, Rheumatoid/drug therapy , Axial Spondyloarthritis/epidemiology , Latent Tuberculosis/drug therapy , Adult , Arthritis, Rheumatoid/epidemiology , Biological Products/therapeutic use , Comorbidity , Female , Humans , Latent Tuberculosis/diagnosis , Latent Tuberculosis/epidemiology , Male , Middle Aged , Morocco/epidemiology , Prevalence , Registries , Retrospective Studies , Tuberculin Test/statistics & numerical data
2.
Rheumatol Int ; 41(4): 787-793, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33386900

ABSTRACT

The aim of the study was to estimate the annual direct costs of biological therapies in rheumatoid arthritis (RA), and to establish possible factors associated with those costs. The main data source was the Moroccan registry of biological therapies in rheumatic diseases (RBSMR Registry). We included patients with available 1-year data. Variables related to socio-economic status, disease and biological therapy were collected. Direct costs included prices of biologics, costs of infusions, and subcutaneous injections. Differences in costs across groups were tested by Mann-Whitney and Kruskal-Wallis tests. Correlations analysis was performed in search of factors associated with high costs. We included 197 rheumatoid arthritis patients. The mean age was 52.3 ± 11 years, with female predominance 86.8%. Receiving one of the following therapies: rituximab (n = 132), tocilizumab (n = 37), or TNF-blockers (n = 28). Median one-year direct costs per patient were €1665 [€1472-€9879]. The total annual direct costs were € 978,494. Rituximab, constituted 25.7% of the total annual budget. TNF-blockers and tocilizumab represented 27.3% and 47% of this overall budget, respectively. Although the costs were not significantly different in terms of gender or level of study, the insurance type significantly affected the cost estimation. A positive correlation was found between the annual direct cost and body mass index (r = 0.15, p = 0.04). In Morocco, a developing country, the annual direct costs of biological therapy are high. Our results may contribute to the development of strategies for better governance of these costs.


Subject(s)
Antirheumatic Agents/economics , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biological Products/economics , Biological Therapy/economics , Health Care Costs/statistics & numerical data , Adult , Antibodies, Monoclonal, Humanized/economics , Antibodies, Monoclonal, Humanized/therapeutic use , Arthritis, Rheumatoid/economics , Biological Factors/therapeutic use , Biological Products/therapeutic use , Cost-Benefit Analysis , Etanercept/economics , Etanercept/therapeutic use , Female , Health Expenditures , Humans , Male , Middle Aged , Morocco , Rituximab/economics , Rituximab/therapeutic use
3.
BMC Musculoskelet Disord ; 17: 268, 2016 07 11.
Article in English | MEDLINE | ID: mdl-27401188

ABSTRACT

BACKGROUND: Osteoporosis is a well-known complication of ankylosing spondylitis (AS). However, data about body composition modifications and muscle performance showed conflicting results. The aim of the study was to determine the prevalence and risk factors of pre-sarcopenia, sarcopenia and cachexia in patients with AS and analyze its relationship with bone loss and symptomatic and severity parameters of the disease. METHODS: Sixty-seven consecutive male patients with AS (mean age of 40.9 ± 11.0 years) and 67 healthy controls were studied. Body composition and bone mineral density (BMD) scans were obtained using DXA. The fat-free mass index (FFMI; fat-free mass divided by height squared) and the percent of fat mass (%FM) were calculated. Pre-sarcopenia was defined by low skeletal muscle mass (SMI <7.25 kg/m(2)), sarcopenia by the combined presence of the two following criteria: SMI <7.25 kg/m(2) and a low muscle strength (handgrip strength <30 kg) or a low muscle performance (timed get-up-and-go test >10 s) and cachexia by a BMI <20 kg/m(2) plus 3 from the 5 following parameters: anorexia, fatigue, handgrip strength <30 kg, CRP >5 mg/l, SMI <7.25 kg/m(2). RESULTS: Pre-sarcopenia, sarcopenia, cachexia, and osteoporosis prevalences were (50.4, 34.3, 11.9, and 16.0) respectively. Patients had a mean 3 kg significant decrease in FFM and a 1 kg/m(2) decrease in appendicular mass vs. healthy controls. Pre-sarcopenia, sarcopenia and cachexia were significantly associated to higher BASDAI levels and low BMD. CONCLUSION: Our study showed that men with AS had a statistically significant reduction in total and appendicular lean mass that is related to higher disease activity and significantly associated to bone loss.


Subject(s)
Cachexia/epidemiology , Osteoporosis/epidemiology , Sarcopenia/epidemiology , Spondylitis, Ankylosing/complications , Absorptiometry, Photon , Adult , Aged , Body Composition , Body Mass Index , Bone Density , Cachexia/etiology , Hand Strength , Humans , Male , Middle Aged , Muscle Strength , Osteoporosis/diagnostic imaging , Osteoporosis/etiology , Prevalence , Risk Factors , Sarcopenia/etiology , Young Adult
4.
BMC Womens Health ; 15: 41, 2015 May 13.
Article in English | MEDLINE | ID: mdl-25968889

ABSTRACT

BACKGROUND: Vertebral Fractures (VFs) are associated with bone loss that occurs before menopause but is accelerated at menopause as a result of sex hormone deficiency. To determine the association of sex hormones, bone remodeling markers and vitamin D levels with bone mineral density (BMD) and asymptomatic VFs prevalence using vertebral fracture assessment (VFA) in a cohort of Moroccan menopausal women. METHODS: This was a cross-sectional study conducted from October 2012 to April 2013 with menopausal women aged 50 years old and over. A total of 207 women who had no previous diagnosis of osteoporosis were enrolled in this cross-sectional study. Women were recruited prospectively from our laboratory department. VFA images and scans of the lumbar spine and proximal femur were obtained using a GE Healthcare Lunar Prodigy densitometer. VFs were defined using a combination of Genant semiquantitative approach and morphometry. Serum levels of estradiol, dehydroepiandrosterone sulfate, Sex hormone binding globulin, vitamin D, Osteocalcin, Crosslaps, intact parathormone were measured by Electrochemiluminescent immunoassay technique. RESULTS: Among the 207 women, 18.3 % (n = 38) had densitometric osteoporosis. On VFA, VFs were detected in 134 (62.3 %), including 96 (44.6 %) grade 1 and 38 (17.6 %) grade 2/3. There was no difference in the plasma levels of sex steroids, bone remodeling markers and vitamin D in the group of women with VFs (grade 1 and grade 2/3) and without VFs. The combination of variables that best predicted grade 2/3 VFs included the number of years since menopause and the lumbar spine T-score. CONCLUSION: These data confirm the importance of postmenopausal estrogen and SHBG concentrations in the bone loss and the pathogenesis of osteoporosis in elderly women, but not in the occurrence of the VFs.


Subject(s)
Gonadal Steroid Hormones/blood , Osteoporosis, Postmenopausal , Postmenopause/physiology , Spinal Fractures , Vitamin D/blood , Absorptiometry, Photon/methods , Aged , Bone Density , Cross-Sectional Studies , Female , Humans , Middle Aged , Morocco/epidemiology , Osteoporosis, Postmenopausal/blood , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/diagnosis , Osteoporosis, Postmenopausal/epidemiology , Spinal Fractures/epidemiology , Spinal Fractures/etiology
5.
BMC Endocr Disord ; 14: 93, 2014 Dec 10.
Article in English | MEDLINE | ID: mdl-25492884

ABSTRACT

BACKGROUND: The combined effect of the metabolic syndrome (MS) risk factors on bone health has led to controversial results and it is still not clear whether this effect is protective or detrimental. The study aimed to examine the association between MS and bone mineral density (BMD), osteoporosis, and vertebral fractures (VFs) among ambulatory older postmenopausal women. METHODS: 270 post-menopausal women with a mean age of 61.0 years ± 7.8 (50 to 90) with no prior known diagnosis of osteoporosis were recruited. BMD and Lateral vertebral fracture assessment (VFA) images were obtained using a GE Healthcare Lunar Prodigy densitometer. VFs were defined using a combination of Genant semiquantitative approach and morphometry. RESULTS: The MS as defined by the NCEP-ATP III was present in 62 women (23.0%). According to the WHO classification, 82 had osteoporosis at any site (30.4%). VFs were identified in 116 (43.0%): 80 (29.6%) had grade 1 and 36 (13.3%) had grade 2 or 3. Women with MS had a significantly higher BMD and lower prevalence of osteoporosis (17.7% vs. 34.1%) than those without MS. No significant statistical difference was noted in prevalence of VFs (14.5 vs. 13.0%). There were significantly less women with MS among the group of osteoporotic women (13% vs. 27%; p = 0.018). Conditional regression binary analysis assessing the presence of osteoporosis as the dependent variable showed that women with a MS had a significant 71% decrease in the odds of being osteoporotic by BMD compared with women who had not MS accounting for age, BMI, number of parities and years since menopause. CONCLUSION: Women with MS had higher BMD at the hip and spine, suggesting a protective effect of MS on bone. However, the prevalence of VFs was similar between women with or without MS.


Subject(s)
Hip/pathology , Metabolic Syndrome/complications , Metabolic Syndrome/metabolism , Osteoporosis, Postmenopausal/metabolism , Postmenopause/metabolism , Spinal Fractures/metabolism , Spine/pathology , Absorptiometry, Photon , Aged , Aged, 80 and over , Alcohol Drinking/adverse effects , Bone Density , Cross-Sectional Studies , Dairy Products , Female , Humans , Male , Middle Aged , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/pathology , Prevalence , Risk Factors , Smoking/adverse effects , Spinal Fractures/etiology , Spinal Fractures/prevention & control , Women's Health
6.
BMC Musculoskelet Disord ; 15: 365, 2014 Nov 04.
Article in English | MEDLINE | ID: mdl-25366306

ABSTRACT

BACKGROUND: A Moroccan model for the FRAX tool to determine the absolute risk of osteoporotic fracture at 10 years has been established recently. The study aimed to assess the discriminative capacity of FRAX in identifying women with prevalent asymptomatic vertebral fractures (VFs). METHODS: We enrolled in this cross-sectional study 908 post-menopausal women with a mean age of 60.9 years ± 7.7 (50 to 91) with no prior known diagnosis of osteoporosis. Subjects were recruited from asymptomatic women selected from the general population. Lateral VFA images and scans of the lumbar spine and proximal femur were obtained using a GE Healthcare Lunar Prodigy densitometer. VFs were defined using a combination of Genantsemiquantitative (SQ) approach and morphometry. We calculated the absolute risk of major fracture and hip fracture with and without bone mineral density (BMD)using the FRAX website.The overall discriminative value of the different risk scores was assessed by calculating the areas under the ROC curve (AUC). RESULTS: VFA images showed that 179 of the participants (19.7%) had at least one grade 2/3 VF. The group of women with VFs had a statistically significant higher FRAX scores for major and hip fractures with and without BMD, and lower weight, height, and lumbar spine and hip BMD and T-scores than those without a VFA-identified VF. The AUC ROC of FRAX for major fracture without BMD was 0.757 (CI 95%; 0.718-0.797) and 0.736 (CI 95%; 0.695-0.777) with BMD, being 0.756 (CI 95%; 0.716-0.796) and 0.747 (CI 95%; 0.709-0.785), respectively for FRAX hip fracture without and with BMD. The AUC ROC of lumbar spine T-score and femoral neck T-score were 0.660 (CI 95%; 0.611-0.708) and 0.707 (CI 95%; 0.664-0.751) respectively. CONCLUSION: In asymptomatic post-menopausal women, the FRAX risk for major fracture without BMD had a better discriminative capacity in identifying the women with prevalent VFs than lumbar spine and femoral neck T-scores suggesting its usefulness in identifying women in whom VFA could be indicated.


Subject(s)
Absorptiometry, Photon/standards , Algorithms , Spinal Fractures/diagnostic imaging , Spinal Fractures/epidemiology , World Health Organization , Absorptiometry, Photon/methods , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Humans , Middle Aged , Morocco/epidemiology , Prevalence
7.
Ann Afr Med ; 23(3): 267-270, 2024 Jul 01.
Article in French, English | MEDLINE | ID: mdl-39034546

ABSTRACT

INTRODUCTION: Our purpose was to study the body composition in a healthy female Moroccan adult group, and to help physicians to evaluate nutritional status. MATERIALS AND METHODS: Five hundred and nineteen healthy women aged from 20 to 80 years were included in the study. Bone mineral density at the hip and lumbar spine and the body composition parameters were measured by dual-energy X-ray absorptiometry: fat mass (FM), fat-free mass (FFM), and percentage (%) of body fat. The FFM index (FFMI) and the FM index (FMI) were calculated. We analyzed the population by age and body mass index (BMI) defined groups. RESULTS: The mean age of the population was 53.14 ± 13.69 years with an average BMI of 29.30 ± 5.04 kg/m2. Means of FM and FFM were 33.93 ± 9.18 kg and 36.91 ± 5 kg, respectively, with FM and FFMI of 13.65 ± 3.66 kg/m2 and 14.85 ± 1.91 kg/m2, respectively. The % FM, FFM, and their corresponding indices increased with age; a statistically significant difference was observed between the 20 and 39 age categories and the two other categories. The BMI category analysis showed that FFMI and FMI increased in obese women with a statistically significant difference between the four groups. Age and BMI were correlated significantly with the different parameters. CONCLUSION: This is the first Moroccan study to present body composition indexes in healthy Moroccan female adults. These reference values may be useful for the clinical evaluation of body composition and nutritional status.


Résumé Introduction:Notre objectif était d'étudier la composition corporelle dans un groupe adulte marocain féminin en bonne santé et d'aider les médecins à évaluer l'état nutritionnel.Matériaux et méthodes:Cinq cent dix-neuf femmes en bonne santé âgées de 20 à 80 ans ont été incluses dans l'étude. La densité minérale osseuse à la hanche et la colonne vertébrale lombaire et les paramètres de composition corporelle ont été mesurées par absorptiométrie à double énergie X: masse grasse (FM), masse sans graisse (FFM) et pourcentage (%) de graisse corporelle. L'indice FFM (FFMI) et l'indice FM (FMI) ont été calculés. Nous avons analysé la population par des groupes définis par l'âge et l'indice de masse corporelle (IMC).Résultats:L'âge moyen de la population était de 53,14 ± 13,69 ans avec un IMC moyen de 29,30 ± 5,04 kg / m2. Les moyennes de FM et de FFM étaient de 33,93 ± 9,18 kg et 36,91 ± 5 kg, respectivement, avec FM et FFMI de 13,65 ± 3,66 kg / m2 et 14,85 ± 1,91 kg / m2, respectivement. Le% FM, FFM et leurs indices correspondants ont augmenté avec l'âge; Une différence statistiquement significative a été observée entre les 20 et 39 catégories d'âge et les deux autres catégories. L'analyse de la catégorie IMC a montré que l'IFMI et l'IFM ont augmenté chez les femmes obèses avec une différence statistiquement significative entre les quatre groupes. L'âge et l'IMC étaient corrélés de manière significative avec les différents paramètresConclusion:il s'agit de la première étude marocaine à présenter des indices de composition corporelle chez des adultes marocains sains. Ces valeurs de référence peuvent être utiles pour l'évaluation clinique de la composition corporelle et de l'état nutritionnel.


Subject(s)
Absorptiometry, Photon , Body Composition , Body Mass Index , Bone Density , Nutritional Status , Obesity , Humans , Female , Adult , Middle Aged , Body Composition/physiology , Morocco/epidemiology , Obesity/epidemiology , Aged , Bone Density/physiology , Young Adult , Aged, 80 and over , Adipose Tissue/diagnostic imaging
8.
Arch Osteoporos ; 19(1): 61, 2024 Jul 18.
Article in English | MEDLINE | ID: mdl-39026053

ABSTRACT

INTRODUCTION: This systematic review and meta-analysis was conducted as part of the update of Moroccan recommendations for the management of postmenopausal osteoporosis. Its aim was to estimate the prevalence of postmenopausal osteoporosis in Morocco, based on available bibliographic data. METHODS: We conducted a systematic search of the Medline/PubMed, Scopus, and Embase databases to identify articles published between January 2000 and January 2024. We included all observational studies reporting the prevalence of osteoporosis in postmenopausal women in Morocco. Two reviewers independently contributed to the study selection and data extraction. We assessed the risk of bias in the included studies using the Joanna Briggs Institute tool. Statistical analyses were performed using Stata with the Freeman-Tukey double arcsine transformation. Heterogeneity was assessed using the I2 test statistic. Meta-regression analysis was used to investigate the effect of the date on the prevalence. Publication bias was assessed by DOI plots and the LFK index. RESULTS: An electronic search found a total of 161 citations from the databases. After excluding the irrelevant articles, 17 eligible studies were included. This meta-analysis included 5097 postmenopausal women. The pooled prevalence of postmenopausal osteoporosis was 32% (95% CI 28-36). Heterogeneity was statistically significant (I2 = 89.67%). There was no significant difference between subgroup analyses performed by risk of bias and sample size. The prevalence rate was significantly higher in 2006-2012 (36%; 95% CI 31-42; I2 = 88.7%; p < 0.001) than in 2013-2019 (27%; 95% CI 22-32; I2 = 85.9%; p < 0.001). Meta-regression showed that the prevalence of osteoporosis decreases very slightly (0.016% per year). This decrease becomes nonsignificant if only studies with a low risk of bias are included in the meta-regression (coefficient - 7.77, p = 0.667, I2 0%). No publication bias was detected in this meta-analysis. CONCLUSION: Our results indicate that postmenopausal osteoporosis is prevalent in Morocco, which is a developing country; however, the prevalence of this disease is aligned with that of industrialized countries.


Subject(s)
Osteoporosis, Postmenopausal , Humans , Morocco/epidemiology , Osteoporosis, Postmenopausal/epidemiology , Female , Prevalence
9.
Arch Osteoporos ; 18(1): 59, 2023 05 02.
Article in English | MEDLINE | ID: mdl-37129714

ABSTRACT

The prevalence of glucocorticosteroid-induced osteoporosis (GIOP) is well established in higher income countries. There are limited studies showing a wide prevalence of GIOP in Africa. Prospective studies are needed on GIOP in African rheumatology patients to implement appropriate management algorithms. PURPOSE: The prevalence of glucocorticosteroid-induced osteoporosis (GIOP) is well established in developed countries, but little is known about GIOP in African adult patients with inflammatory rheumatic musculoskeletal diseases (RMDs). This study aimed to determine the prevalence of GIOP and osteoporotic fracture risk in African patients with inflammatory RMDs according to radiographic and bone mineral density (BMD) findings. METHODS: PubMed, Google Scholar, Scopus, and African Index Medicus were searched up to 31 December 2020. Heterogeneity was assessed using I2 statistic across the included studies. A random-effects model was applied to estimate the pooled effect size across studies. All statistical analyses were performed using STATA™ version 14 software. The study was registered with PROSPERO, number CRD42021256252. RESULTS: In this meta-analysis, a total of 7 studies with 780 participants, stratified by geographical region were included. The pooled prevalence of GIOP based on BMD data was 47.7% (95% CI 32.9-62.8) with 52.2% (95% CI 36.5-67.6) in North African countries and 15.4% (95% 1.9-45.4%) in South Africa with a high heterogeneity (I2 = 93.3%, p = 0.018). There was no data from the rest of African countries. We were unable to complete the meta-analysis of osteoporotic fractures due to the lack of available data. CONCLUSION: This study revealed that the prevalence of GIOP varies significantly in Africa. There is no information, however, for most of Africa, and further prospective studies are needed to develop context-specific GIOP preventive strategies in patients with RMDs.


Subject(s)
Musculoskeletal Diseases , Osteoporosis , Osteoporotic Fractures , Rheumatology , Adult , Humans , Glucocorticoids/adverse effects , Prevalence , Osteoporosis/chemically induced , Osteoporosis/epidemiology , Osteoporosis/prevention & control , Osteoporotic Fractures/chemically induced , Osteoporotic Fractures/epidemiology , South Africa
10.
Tunis Med ; 101(7): 609-611, 2023 Jul 05.
Article in English | MEDLINE | ID: mdl-38445421

ABSTRACT

AIM: To address the protocol of recommendations for the use of ultrasonography (US) in the management of rheumatoid arthritis (RA) in routine practice. METHODS: The present study is a protocol design for practical guidelines. Based on a systematic literature review, the scientific committee (composed of 6 experts on US) decided on key questions which will be used to develop recommendations. These recommendations will be submitted to a group of experts in US in rheumatic and musculoskeletal diseases using the Delphi method. This step will lead to preliminary recommendations. The next step will be to submit the preliminary guideline to an expanded group of US experts to check their relevance. The level of agreement of the experts will be recorded during a web-based meeting. RESULTS: Following two rounds of the Delphi method, a consensus will be addressed. The latter will i) Highlight the use of US for the diagnosis of RA in an early stage of the disease; ii) Define the role of US during follow-up; and iii) Underline the importance of US for the management of clinical remission. CONCLUSION: These recommendations will harmonize and optimize clinical practice and management of RA patients.


Subject(s)
Arthritis, Rheumatoid , Musculoskeletal Diseases , Practice Guidelines as Topic , Ultrasonography , Humans , Arthritis, Rheumatoid/diagnostic imaging , Consensus , Musculoskeletal Diseases/diagnostic imaging , Systematic Reviews as Topic
11.
Cureus ; 15(5): e39100, 2023 May.
Article in English | MEDLINE | ID: mdl-37273389

ABSTRACT

Introduction The Assessment of SpondyloArthritis International Society (ASAS) criteria for axial and peripheral spondyloarthritis (SpA) allow for the classification of patients with an age of onset of disease of less than 45 years. However, SpA can start after this age. This study aimed to assess the characteristics of late-onset SpA (SpA>45 years) in the Moroccan registry of biological therapies in rheumatic diseases (RBSMR). Methods A cross-sectional study was conducted using the baseline data of the RBSMR. The protocol for the original RBSMR study was reviewed and approved by the Ethics Committee for Biomedical Research Mohammed V University - Rabat, Faculty of Medicine and Pharmacy of Rabat (approval number for the study was 958/09/19, and the date of approval was September 11, 2019), and all patients had given their written consent. Patients who met the 2009 ASAS criteria for SpA were included. They were divided into two groups: early-onset SpA (≤ 45 years) and late-onset SpA (>45 years). Clinical, biological, radiological, and therapy data of the two groups were compared. Statistical analysis was performed using SPSS v25 software (IBM Corp. Armonk, NY). Parameters with a p-value ≤0.05 were considered significant. Results Our population consisted of 194 patients. Thirty-one patients (16%) had late-onset SpA. Comparison between patients with early-onset (≤45 years) and late-onset SpA (>45 years) revealed that late-onset SpA had a higher tender joint count (p=0.01), a higher swollen joint count (p=0.02), depression (p=0.00), fibromyalgia (p=0.001), hypercholesterolemia (p=0.01), and a lower frequency of coxitis (p=0.008). Logistic regression analysis confirmed that late-onset SpA was associated with a higher tender joint count (OR=0.93, CI 95%: 0.88-0.98), a higher swollen joint count (OR=0.92, CI 95%: 0.85-0.99), depression ( OR=0.19, CI 95%:0.04-0.38), fibromyalgia (OR=1.75, CI 95%: 1.74-17.85), and a lower frequency of coxitis ( OR=0.29, CI 95%: 0.11-0.75). Conclusion As life expectancy increases, late-onset SpA will become increasingly common. It is therefore imperative to determine its characteristics. In the RBSMR study, late-onset SpA was associated with a high number of tender and swollen joints, depression, fibromyalgia, and a lower frequency of coxitis.

13.
Rheumatology (Oxford) ; 51(9): 1714-20, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22661554

ABSTRACT

OBJECTIVE: To study the relationship between the prevalence of vertebral fractures (VFs) using VF assessment (VFA) in asymptomatic men and the prevalence and severity of abdominal aortic calcification (AAC). METHODS: We enrolled 709 men with mean (s.d.) age 62.4 (8.6) (range 45-89) years. Lateral VFA images and scans of the lumbar spine and proximal femur were obtained using a GE Healthcare Lunar Prodigy densitometer. VFs were defined using a combination of the Genant semi-quantitative (SQ) approach and morphometry. VFA images were scored for AAC using a validated 24-point scale. RESULTS: VFA images showed that 68 (14.2%) of the participants had at least one grade 2/3 VF, 82% did not have any detectable AAC, whereas the prevalence of significant atherosclerotic burden, defined as an AAC score of ≥5, was 2.8%. The group of men with grade 2/3 VFs had a statistically significant higher AAC score and higher proportion of subjects with extended AAC, and lower weight, height and lumbar spine and hip BMD and T-scores than those without a VFA-identified VF. Multiple regression analysis showed that the presence of grade 2/3 VFs was significantly associated with BMI [odds ratio (OR 0.915; 95% CI 0.589, 0.975; P = 0.006], AAC score ≥5 (OR 4.509; 95% CI 1.505, 13.504; P = 0.007) and osteoporosis in any site (OR 5.159; 95% CI 3.116, 8.540; P ≤ 0.0001). CONCLUSION: In elderly men, extended AAC is an indicator of the increased risk for prevalent VFs regardless of age, BMI, history of fractures, smoking and BMD.


Subject(s)
Aorta, Abdominal/pathology , Calcinosis/epidemiology , Osteoporotic Fractures/epidemiology , Spinal Fractures/epidemiology , Absorptiometry, Photon , Aged , Aged, 80 and over , Aorta, Abdominal/diagnostic imaging , Bone Density , Calcinosis/diagnosis , Comorbidity , Humans , Male , Middle Aged , Morocco/epidemiology , Osteoporotic Fractures/diagnosis , Prevalence , Shoulder Fractures/diagnosis , Shoulder Fractures/epidemiology , Spinal Fractures/diagnosis
14.
J Clin Densitom ; 15(3): 328-33, 2012.
Article in English | MEDLINE | ID: mdl-22321654

ABSTRACT

The objective of this study was to examine the influence of homocysteine, vitamin B(12), and folate on the prevalence of asymptomatic osteoporotic vertebral fractures (VFs) using vertebral fracture assessment (VFA) in postmenopausal women. The study cohort consisted of 188 consecutive postmenopausal women (mean age, weight, and body mass index of 57.9 ± 8.5 [41-91]yr, 74.4 ± 13.5 [38-150]kg, and 30.4 ± 5.2 [17.1-50.7]kg/m(2), respectively). Lateral VFA images and scans of the lumbar spine and proximal femur were obtained using a Lunar Prodigy Vision densitometer (GE Healthcare Inc., Waukesha, WI). VFs were defined using a combination of Genant's semiquantitative approach and morphometry. Fifty-eight (30.9%) patients had densitometric osteoporosis. VFs were identified using VFA in 76 (40.4%) patients: 61 women had grade 1 VFs and 15 had grade 2 or 3 VFs. No statistical difference was shown between the 3 groups (absence of VFs, VFs grade 1, and VFs grade 2/3) concerning the biological parameters. Comparison of patients according to quartiles of homocysteine levels showed that women in the highest quartile were older and had a lower bone mineral density (BMD); however, the prevalence of VFs was not statistically different from that of women in the other quartile groups. Stepwise regression analysis showed that homocysteine was not independently associated with the presence of VFs, which was mainly related to the osteoporotic status. Although a weak association was observed between hyperhomocysteinemia and low BMD and a trend to higher prevalence of grade 2/3 VFs was observed, our study did not confirm that homocysteine, vitamin B(12), and folate status are important determinants of prevalent asymptomatic VFs in postmenopausal women.


Subject(s)
Folic Acid/blood , Homocysteine/blood , Osteoporosis, Postmenopausal/epidemiology , Osteoporotic Fractures/epidemiology , Spinal Fractures/epidemiology , Vitamin B 12/blood , Adult , Aged , Aged, 80 and over , Female , Humans , Hyperhomocysteinemia/epidemiology , Middle Aged , Risk Assessment
15.
BMC Womens Health ; 12: 11, 2012 Apr 24.
Article in English | MEDLINE | ID: mdl-22531050

ABSTRACT

BACKGROUND: Hypovitaminosis D is associated to accentuated bone loss. However, association between osteoporotic vertebral fractures (VFs) and vitamin D status has not been clearly established. OBJECTIVE: To determine serum vitamin D status and to assess the association of vitamin D status with bone mineral density (BMD) and asymptomatic VFs prevalence using vertebral fracture assessment (VFA) in a cohort of Moroccan menopausal women. METHODS: from June to September 2010, 178 menopausal women 50 years old and over were enrolled in this cross-sectional study. The mean ± SD (range) age, weight, height and BMI were 58.8 ± 8.2 (50 to 79) years, 73.2 ± 13.8 (35 to 119) Kgs, 1.56 ± 0.06 (1.43 - 1.79) m and 29.8 ± 5.9 (17.5 - 49.8) kg/m2, respectively. VFA images and scans of the lumbar spine and proximal femur were obtained using a GE Healthcare Lunar Prodigy densitometer. VFs were defined using a combination of Genant semiquantitative approach and morphometry. Serum levels of 25-hydroxyvitamin D (25(OH)D) were measured. RESULTS: Among the 178 women, 45 (25.2%) had densitometric osteoporosis, and on VFA, VFs (grade 2 or 3) were detected in 20.2% while grade 1 were identified in 33.1%. The mean values of serum levels of 25(OH)D were 15.8 ± 11.6 ng/ml (range: 3.0 - 49.1) with 152 patients (85.3%) having levels <30 ng/ml (insufficiency) and 92 (51.6%) <10 ng/ml (deficiency). Stepwise regression analysis showed that presence of VFs was independently related to age, 25(OH)D and densitometric osteoporosis. CONCLUSION: our study shows that advanced age, hypovitaminosis D and osteoporosis are independent risk factors for asymptomatic VFs in Moroccan postmenopausal women.


Subject(s)
Bone Density , Postmenopause , Spinal Fractures/epidemiology , Vitamin D Deficiency/epidemiology , Vitamin D/analogs & derivatives , Women's Health , Age Factors , Aged , Cohort Studies , Cross-Sectional Studies , Female , Humans , Middle Aged , Morocco/epidemiology , Osteoporosis/complications , Osteoporosis/epidemiology , Prevalence , Risk Factors , Spinal Fractures/etiology , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/complications
16.
Rheumatol Int ; 32(1): 123-8, 2012 Jan.
Article in English | MEDLINE | ID: mdl-20676649

ABSTRACT

To test whether in Moroccan healthy postmenopausal women, levels of plasma total homocysteine (tHcy), folate, and vitamin B12 are related to BMD. A total of 188 volunteer postmenopausal women were recruited from our blood taking center between April 2008 and December 2008. Each subject completed a standardized questionnaire designed to document putative risk factors of osteoporosis. Bone mineral density was determined by a Lunar Prodigy Vision DXA system, and blood samples for plasma tHcy, folate, vitamin B12, and serum parathyroid hormone (PTH) were taken. Comparison between women with osteoporosis, osteopenia and normal BMD showed that the osteoporotic women were significantly older, had lower weight and height than the women of the other groups. Plasma tHcy was significantly higher in the osteoporotic group. Levels of tHcy were inversely related to BMD at the lumbar spine, at the total hip and plasma vitamin B12 and positively related to age and creatinine. Multiple regression analysis showed that age and BMI were the main predictors of BMD at the lumbar spine, whereas the main predictors of BMD at the total hip were age, BMI, plasma tHcy, and plasma vitamin B(12). tHcy and vitamin B12 are independent risk factors for osteoporosis in Moroccan healthy postmenopausal women.


Subject(s)
Bone Density/physiology , Bone Diseases, Metabolic/blood , Folic Acid/blood , Homocysteine/blood , Osteoporosis, Postmenopausal/blood , Postmenopause/blood , Vitamin B 12/blood , Absorptiometry, Photon , Age Factors , Aged , Body Mass Index , Bone Diseases, Metabolic/epidemiology , Bone Diseases, Metabolic/physiopathology , Cross-Sectional Studies , Female , Humans , Lumbar Vertebrae/diagnostic imaging , Middle Aged , Morocco , Osteoporosis, Postmenopausal/epidemiology , Osteoporosis, Postmenopausal/physiopathology , Parathyroid Hormone/blood , Postmenopause/ethnology , Postmenopause/physiology , Retrospective Studies , Risk Factors
17.
Tunis Med ; 100(7): 514-519, 2022.
Article in English | MEDLINE | ID: mdl-36571739

ABSTRACT

INTRODUCTION: A potential role of hyperhomocysteinemia in bone metabolism has been considered from the observation of high prevalence of osteoporosis in subjects with homocystinuria about 50 years ago. AIM: To examine the association of homocysteine level and its determinants Methylenetetrahydrofolate Reductase [MTHFR] C677T Polymorphism, folates and vitamin B12 levels with bone mineral density [BMD] and the prevalence of vertebral fractures [VF] on postmenopausal women. METHODS: Through a cross-sectional study, one hundred and twenty-two healthy postmenopausal women gave their informed consent to participate in this study. Women were recruited through advertisements and mouth to ear between January 2017 and May 2017. One serum tube and one EDTA tube were collected from fasting patients. Bone mineral density was determined by a Lunar Prodigy® Vision DXA system®. Vertebral fracture [VF] assessment image was inspected visually by 2 clinicians. RESULTS: We found that a high level of homocysteine and low vitamin B12 and folate levels are not associated with bone mineral density and are not risk factors for VF in healthy postmenopausal women. Whereas, the presence of VF was associated with the number of years since menopause and with the osteocalcin levels. CONCLUSION: The MTHFR C677T polymorphism, the high levels of HCY, or low levels of folate and vitamin B12 would not be risk factors for osteoporosis and VF in healthy postmenopausal women.


Subject(s)
Osteoporosis , Spinal Fractures , Humans , Female , Bone Density/genetics , Cross-Sectional Studies , Homocysteine , Folic Acid , Vitamin B 12
18.
Arch Osteoporos ; 16(1): 176, 2021 11 18.
Article in English | MEDLINE | ID: mdl-34792646

ABSTRACT

The objective of this consensus statement is to inform the clinical practice communities, research centres and policymakers across Africa of the results of the recommendations for osteoporosis prevention, diagnosis and management. The developed guideline provides state-of-the-art information and presents the conclusions and recommendations of the consensus panel regarding these issues. PURPOSE: To reach an African expert consensus on a treat-to-target strategy, based on current evidence for best practice, for the management of osteoporosis and prevention of fractures. METHOD: A 3-round Delphi process was conducted with 17 osteoporosis experts from different African countries. All rounds were conducted online. In round 1, experts reviewed a list of 21 key clinical questions. In rounds 2 and 3, they rated the statements stratified under each domain for its fit (on a scale of 1-9). After each round, statements were retired, modified or added in view of the experts' suggestions and the percent agreement was calculated. Statements receiving rates of 7-9 by more than 75% of experts' votes were considered as achieving consensus. RESULTS: The developed guidelines adopted a fracture risk-centric approach. Results of round 1 revealed that of the 21 proposed domains, 10 were accepted whereas 11 were amended. In round 2, 32 statements were presented: 2 statements were retired for similarity, 9 statements reached consensus, whereas modifications were suggested for 21 statements. After the 3rd round of rating, the experts came to consensus on the 32 statements. Frequency of high-rate recommendation ranged from 83.33 to 100%. The response rate of the experts was 100%. An algorithm for the osteoporosis management osteoporosis was suggested. CONCLUSION: This study is an important step in setting up a standardised osteoporosis service across the continent. Building a single model that can be applied in standard practice across Africa will enable the clinicians to face the key challenges of managing osteoporosis; furthermore, it highlights the unmet needs for the policymakers responsible for providing bone health care together with and positive outcomes of patients' care.


Subject(s)
Fractures, Bone , Osteoporosis , Bone Density , Consensus , Delphi Technique , Fractures, Bone/prevention & control , Humans , Osteoporosis/diagnosis , Osteoporosis/drug therapy
19.
Rheumatology (Oxford) ; 49(7): 1303-10, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20360038

ABSTRACT

OBJECTIVE: To study the prevalence and risk factors of vertebral fractures (VFs) in a large cohort of patients with RA using VF assessment (VFA). METHODS: We enrolled 172 women with RA, none of whom were taking osteoporosis medications. Patients underwent dual X-ray absorptiometry at the hip and spine and VFA, and completed a questionnaire. Radiological status was assessed by the modified Sharp erosion and narrowing score. VFA was classified using a combination of Genant semi-quantitative approach and morphometry. RESULTS: Patients had a mean (s.d.) disease duration of 8.4 (5.2) years. VFs were detected in 36% (62/172). This group of women had a statistically significant lower weight, height and lumbar spine and total hip BMD and T-scores than those without a VFA-identified VF. They also had more long-standing and severe disease and a greater consumption of corticosteroids. Stepwise regression analysis showed that the presence of VFs was independently associated with low weight and total hip T-score and long disease duration, CRP and Sharp erosion score. CONCLUSION: RA is a risk factor on its own for the development of osteoporosis and VFs and this risk increases more with low weight, disease duration and severe course of disease. These findings may suggest that to prevent the development of VFs, precautions should be taken immediately to suppress the disease activity and correct the weight loss in patients with RA.


Subject(s)
Arthritis, Rheumatoid/complications , Osteoporosis/complications , Spinal Fractures/etiology , Absorptiometry, Photon/methods , Adult , Aged , Bone Density , Cohort Studies , Female , Humans , Lumbar Vertebrae/diagnostic imaging , Middle Aged , Predictive Value of Tests , Prevalence , Regression Analysis , Risk Factors , Spinal Fractures/diagnostic imaging , Surveys and Questionnaires , Time Factors
20.
Rheumatol Int ; 30(5): 651-4, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19588143

ABSTRACT

We report the case of a 42-year-old woman who was admitted in 2002 for exploration of diffuse bone pain. She had medical history of pulmonary tuberculosis. Her current symptoms had started 9 months earlier and consisted of bone pain, affecting the legs. She had asthenia and weight loss. At admission, physical examination showed bilateral and symmetrical long bone pain, especially the knees and the ankles. Physical exam was normal elsewhere. Laboratory tests showed inflammation, with an erythrocyte sedimentation rate of 90 mm/h and C-reactive protein 8 mg/l. Protein electrophoresis, red and white blood cell count, renal, and liver function tests were normal. Serum calcium, phosphorus, and urinary calcium were normal. Radiographs showed multiple mixed bone lesions with sclerotic and lytic areas of the femora, tibiae, humerus. Chest radiographs and thoracic computed tomography (CT) scan showed pulmonary fibrosis. Biopsy of the tibial area displayed foamy lipid-laden histiocytes, confirming the diagnosis of Erdheim-Chester disease. Patient was treated with prednisolone plus cyclophosphamide. Her clinical condition improved remarkably during 4 years, but she developed acute renal failure leading to death.


Subject(s)
Acute Kidney Injury/etiology , Bone Diseases/etiology , Erdheim-Chester Disease/complications , Pulmonary Fibrosis/etiology , Acute Kidney Injury/diagnosis , Acute Kidney Injury/drug therapy , Adult , Biomarkers/blood , Biopsy , Bone Density Conservation Agents/therapeutic use , Bone Diseases/diagnosis , Bone Diseases/drug therapy , Drug Therapy, Combination , Erdheim-Chester Disease/diagnosis , Erdheim-Chester Disease/drug therapy , Fatal Outcome , Female , Humans , Immunosuppressive Agents/therapeutic use , Magnetic Resonance Imaging , Pulmonary Fibrosis/diagnosis , Pulmonary Fibrosis/drug therapy , Tomography, X-Ray Computed , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL